MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Long-Term Safety

Search medical newsFind research, conditions and clinical updates
  • Home
  • Long-Term Safety
Ruxolitinib cream治疗儿童特应性皮炎:来自3期TRuE-AD3试验的长期安全性与持续控制结果
Posted inClinical Updates Dermatology Pediatrics

Long-term Safety and Sustained Control of Atopic Dermatitis in Children Treated with Ruxolitinib Cream: Insights from the Phase 3 TRuE-AD3 Trial

Posted by By MedXY 11/12/2026
Ruxolitinib cream demonstrates sustained safety and effective disease control over 52 weeks in children aged 2 to 11 years with mild-to-moderate atopic dermatitis, affirming its role as a promising therapeutic option.
Read More
Sustained Efficacy and Safety of Dupilumab in Children with Moderate to Severe Atopic Dermatitis: Insights from a 3-Year Dutch Cohort Study
Posted inDermatology news Pediatrics

Sustained Efficacy and Safety of Dupilumab in Children with Moderate to Severe Atopic Dermatitis: Insights from a 3-Year Dutch Cohort Study

Posted by By MedXY 10/02/2026
This study highlights dupilumab's long-term effectiveness and safety in managing pediatric atopic dermatitis over 3 years, revealing age-related differences in symptom control and treatment persistence.
Read More
Long-term Efficacy and Safety of Upadacitinib in Alopecia Areata: A Comprehensive Review of Real-World Evidence and Translational Insights
Posted inClinical Updates Dermatology news

Long-term Efficacy and Safety of Upadacitinib in Alopecia Areata: A Comprehensive Review of Real-World Evidence and Translational Insights

Posted by By MedXY 08/16/2026
This review synthesizes current evidence on upadacitinib for alopecia areata, focusing on long-term efficacy, safety, and predictors of treatment response, highlighting the real-world retrospective study by Wang et al. alongside emerging clinical and mechanistic data.
Read More
Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM Study
Posted inCardiology news

Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM Study

Posted by By MedXY 06/28/2026
The FOREST-HCM long-term study confirms aficamten's efficacy and safety in reducing left ventricular outflow tract obstruction and improving symptoms in obstructive hypertrophic cardiomyopathy over nearly one year of treatment.
Read More
Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up
Posted inDiabetes & Endocrinology news

Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up

Posted by By MedXY 06/15/2026
Extended follow-up of participants from 14 randomized trials found no excess self-reported serious adverse outcomes after type 1 diabetes immunotherapy, supporting continued long-term surveillance.
Read More
Long-Term Success of Satralizumab in Managing NMOSD: Insights from the SAkuraMoon Study
Posted inNeurology news

Long-Term Success of Satralizumab in Managing NMOSD: Insights from the SAkuraMoon Study

Posted by By MedXY 10/23/2025
This article reviews the long-term safety and efficacy of satralizumab in neuromyelitis optica spectrum disorder based on the SAkuraMoon extension trial.
Read More
Long-Term Safety of Antenatal Corticosteroids: Insights from the 50-Year Follow-Up of the Auckland Steroid Trial
Posted innews OB/GYN & Women's Health Specialties

Long-Term Safety of Antenatal Corticosteroids: Insights from the 50-Year Follow-Up of the Auckland Steroid Trial

Posted by By MedXY 08/11/2025
The 50-year follow-up study on the Auckland Steroid Trial provides reassurance about the intergenerational safety of antenatal corticosteroid exposure concerning body mass index and various health outcomes in the second generation.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Targeting ANGPTL4 with MAR001: A Promising Approach for Reducing Elevated Triglycerides
  • Enhancing Muscle Endurance: The Impact of Superimposed Tendon Vibration on Isometric Knee Extension Fatigue
  • Enhancing Reactive Balance in Incomplete Spinal Cord Injury: Evaluating the Impact of Functional Electrical Stimulation Combined with Reactive Balance Training
  • Assessing Risks and Safety in Pediatric Dental Sedation: Insights from Claims Data Analysis (2014-2019)
  • Pathotype-Specific Gene Expression Illuminates Genetic Susceptibility in Early Rheumatoid Arthritis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top